Drug Trial Radar · NCT06054113
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Actual
Start
Jul 23, 2024
Primary completion
Jan 6, 2026
Study completion Oct 14, 2027
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Sep 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 204 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of blinatumomab.
Conditions
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Interventions
BlinatumomabDrug
Administered via CIVI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Complete Remission (CR)Time frame: Up to 84 days
- Number of Participants with CR with Partial Recovery of Peripheral Blood Counts (CRh)Time frame: Up to 84 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Childrens Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Wuhan Childrens Hospital
Wuhan, Hubei, China
Children's Hospital of Soochow University
Suzhou, Jiangsu, China
Shanghai Children's Medical Center
Shanghai, Shanghai Municipality, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.